Cole Schotz Advises RFI in Partnership to Create CBD Product Company Infusion Strategies

June 12, 2019Attorney: Jordan A. Fisch
Cole Schotz P.C. represented RFI, LLC in connection with a strategic partnership with Elixinol Global Limited. The partnership was created via a newly incorporated entity, Infusion Strategies, which is owned by Elixinol Global’s wholly-owned subsidiary, Elixinol LLC, and RFI’s affiliate, RFITD Holdings, LLC.

Infusion Strategies will increase Elixinol's exposure to the CBD-infused dietary supplement, nutraceutical, food and beverage industries via distribution to RFI's customers. Elixinol will provide hemp expertise, supply chain stability, highest-quality Full-Spectrum and THC-free Hemp CBD extracts. RFI will manage the day to day operations of Infusion Strategies as well as provide global supply chain management, all non-CBD ingredients and the manufacturing expertise needed to custom blend formulations for tinctures, CBD-infused powders, capsules and other products.

Cole Schotz member Jordan A. Fisch advised RFI, LLC on the strategic partnership.



Hosted on the FirmWise platform.

© Cole Schotz P.C.


The materials on this site have been prepared by Cole Schotz P.C. for general informational purposes only and are not intended to constitute legal advice. Viewers should not act upon this information without seeking professional counsel on the specific facts and circumstances in question from an attorney licensed in their jurisdiction. Use of this site does not create an attorney-client relationship between the user and Cole Schotz or any lawyer(s) within the firm. Any information sent to Cole Schotz or its lawyers through this site will not be treated as confidential and is not protected by the attorney-client privilege.

© Cole Schotz P.C.

Attorney Advertising

This website is an advertisement for a law firm. Statements and previous outcomes do not imply similar results in your matters.

© Cole Schotz P.C.


Thank you for your interest in our publication. Please fill out below and a copy will be sent to your email address.